AstraZeneca: Tezspire Trial Shows Reduced Polyp Size

• Tezspire met primary endpoints in Phase III trial for chronic rhinosinusitis with nasal polyps, showing significant reduction in polyp size and congestion.

Fri Nov 08 08:02:04 -0000 2024 UTC– Tezspire met primary endpoints in Phase III trial for chronic rhinosinusitis with nasal polyps, showing significant reduction in nasal polyps and congestion compared to placebo.

Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:

About Lisa

Subscribe to Lisa’s Newsletter today!

Keep Up: Nobot.News Launches Breaking Newsletter

Read more Business News as it happens!

Business